Uniquity One (uni)
Clinical trials sponsored by Uniquity One (uni), explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New biologic drug solrikitug aims to tame COPD inflammation Results expected Sep 2026 (estimated)
- New drug shows promise for swallowing disorder Results expected Apr 2027 (estimated)
-
New biologic drug solrikitug aims to tame COPD inflammation
Disease control OngoingThis Phase 2 trial tests solrikitug, a biologic drug given as a shot, in 171 adults with moderate-to-severe COPD and high eosinophil levels. The study compares two doses of solrikitug against a placebo to see if it safely reduces inflammation and improves lung function over time.…
Phase 2 • Sponsor: Uniquity One (UNI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New asthma drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests an experimental drug, solrikitug, in 145 adults with asthma who already use daily inhalers. The goal is to see if the drug can safely lower certain immune cells (eosinophils) in the blood and improve asthma control compared to a placebo. It is a Phase 2 trial, me…
Phase 2 • Sponsor: Uniquity One (UNI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug shows promise for swallowing disorder
Disease control OngoingThis study tests an experimental drug called NSI-8226 (solrikitug) in adults with eosinophilic esophagitis, a condition that causes trouble swallowing due to inflamed esophagus. About 184 participants will receive either the drug or a placebo to see if it reduces inflammation and…
Phase 2 • Sponsor: Uniquity One (UNI) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC